SF1 and breast carcinoma: The fact that aromatase inhibitors have proven effective at treating breast cancer induced by adipose aromatase (Brodie et al. 1999) and promise to have similar therapeutic value in endometriosis (Shippen and West 2004) underscores the potential role that atrazine (an aromatase inducer) plays in increasing the risk of these diseases: Aromatase expression and estrogen production is exclusively regulated by ArPII and is SF-1 dependent in endometriosis, a disease that affects 4–6 million women (10% of American women) per year (Bulun et al. 2005).